البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
DILTIAZEM HYDROCHLORIDE
BAUSCH HEALTH, CANADA INC.
C08DB01
DILTIAZEM
120MG
CAPSULE (EXTENDED RELEASE)
DILTIAZEM HYDROCHLORIDE 120MG
ORAL
15G/50G
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0115863004; AHFS:
APPROVED
2001-11-02
_Product Monograph _ _ _ _ _ _ _ _ _ _Page_ _ 1 of 38 _ _Pr_ _TIAZAC_ _®_ _, Diltiazem Hydrochloride Extended-Release Capsules, USP _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TIAZAC ® Diltiazem Hydrochloride, Extended-Release Capsules 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, oral USP ANTIHYPERTENSIVE AGENT ANTIANGINAL AGENT BAUSCH HEALTH, CANADA INC. DATE OF INITIAL AUTHORIZATION: 2150 St-Elzear Blvd. West May 26, 1997 Laval, Quebec H7L 4A8 DATE OF REVISION: December 21, 2022 Control #: 266363 _ _ _Product Monograph Page 2 of 38 _ _Pr_ _TIAZAC_ _®_ _,_ _ _ _Diltiazem Hydrochloride Extended-Release Capsules, USP _ RECENT MAJOR LABEL CHANGES 2. CONTRAINDICATIONS 12/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 4 1 INDICATIONS............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS .............................................................................................. 4 4 DOSAGE AND ADMINISTRATION ............................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ................................................... 5 4.4 Administration.................................................................................................... 5 4.5 Missed Dose.................................................... اقرأ الوثيقة كاملة